在认知保存的非老年人的血神经退行性生物标志物
Estrella Gómez-Tortosa1,2, Pablo Agüero-Rabes1,2, Alicia Ruiz-González3
1Department of Neurology, Fundación Jiménez Díaz, Madrid, Spain.
Aging and disease
|November 21, 2024
概括
认知保存的非老年人表现出明显的血生物标志物概况,神经纤维光链 (NfL) 和质纤维酸蛋白 (GFAP) 的升高表明尽管衰老,大脑的弹性. 这些发现提醒人们不要使用NfL和GFAP来预测老年痴呆症的预后.
科学领域:
- 神经科学是一个神经科学.
- 生物标志物研究 生物标志物研究
- 老年学是一门学科.
背景情况:
- 血生物标志物对于诊断神经退行性疾病,如阿尔茨海默病 (AD) 至关重要.
- 衰老显著影响生物标志物概况,需要对最年长人群进行研究.
- 了解大脑衰老机制和认知保存需要分析非老年人的生物标志物.
研究的目的:
- 分析核心阿尔茨海默病 (AD) 血生物标志物,神经丝光链 (NfL) 和神经纤维酸蛋白 (GFAP) 在认知保存的非老年人中.
- 将这些生物标志物与不同年龄组的认知正常 (CU) 个体以及阿兹海默症患者进行比较.
- 研究衰老,血生物标志物和认知保存之间的关系.
主要方法:
- 利用单分子阵列 (SIMOA) 平台测量等离子体生物标志物.
- 分析了75名认知保存的非老年人,153名CU志愿者 (≤70和71-85岁) 和108名AD患者的样本.
- 在不同组中比较生物标志物水平 (Aß40,Aß42,p-tau181,NfL,GFAP),考虑APOEε4状态.
主要成果:
- 与CU组相比,非老年人表现出明显更高的Aß40,Aß42,p-tau181,NfL和GFAP,以及较低的Aß42/40比.
- 在非老年人与CU组之间,NfL和GFAP水平大约增加了三倍;在年轻和年长的CU组之间没有发现差异.
- 与AD患者相比,非老年人p-tau181较低,但总tau,Aß40,Aß42和NfL较高;GFAP水平与AD患者相似.
结论:
- 认知保存的非老年人没有呈现典型的AD生物标志物签名,并显示Aß42.2的升高.
- 在非老年人中,NfL和GFAP的三倍增长表明他们的老年大脑具有对神经退行症的弹性.
- 血生物标志物在CU个体中保持稳定,直到80岁,NfL/GFAP值需要对痴呆症预后进行谨慎解释.
更多相关视频
08:29Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans
Published on: December 18, 2016
14.0K
06:23The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
32.2K
相关概念视频
01:26Alzheimer's Disease: Overview
448
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
448
01:30Dementia
96
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
96
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
98
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
98
01:22Alzheimer's Disease: Treatment
165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165